Nantahala Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Nantahala Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-164,048	Closed	-$1.85M	–	143
2023 Q2	$1.85M	Sell	164,048 -18,272	-10%	-$86.6K	0.18%	79
2023 Q1	$1.32M	Sell	182,320 -2,132	-1%	-$23.4K	0.1%	91
2022 Q4	$2.07M	Buy	184,452 +36,021	+24%	+$647K	0.13%	75
2022 Q3	$1.95M	Sell	148,431 -6,661	-4%	-$82.3K	0.13%	75
2022 Q2	$1.96M	Buy	155,092 +27,068	+21%	+$949K	0.1%	83
2022 Q1	$7.36M	Buy	128,024 +15,482	+14%	+$1.3M	0.33%	54
2021 Q4	$13.4M	Buy	112,542 +51,864	+85%	+$8.19M	0.47%	46
2021 Q3	$12.1M	Sell	60,678 -6,403	-10%	-$1.12M	0.38%	57
2021 Q2	$11.7M	Sell	67,081 -1,403	-2%	-$255K	0.33%	64
2021 Q1	$13.6M	Sell	68,484 -10,488	-13%	-$2.01M	0.4%	53
2020 Q4	$15.5M	Sell	78,972 -45,965	-37%	-$9.53M	0.48%	49
2020 Q3	$22.1M	Sell	124,937 -3,256	-3%	-$602K	0.68%	32
2020 Q2	$29.6M	Buy	128,193 +14,103	+12%	+$2.69M	0.89%	30
2020 Q1	$13.1M	Hold	114,090	–	–	0.49%	40
2019 Q4	$21.8M	Hold	114,090	–	–	0.67%	37
2019 Q3	$21.9M	Hold	114,090	–	–	0.81%	32
2019 Q2	$19.5M	Buy	114,090 +8,000	+8%	+$1.38M	0.6%	41
2019 Q1	$21.4M	Buy	106,090 +5,000	+5%	+$1.04M	0.67%	35
2018 Q4	$18.9M	Hold	101,090	–	–	0.58%	43
2018 Q3	$24.2M	Buy	101,090 +12,568	+14%	+$2.94M	0.65%	39
2018 Q2	$23.4M	Buy	88,522 +14,735	+20%	+$3.63M	0.95%	30
2018 Q1	$18.3M	Hold	73,787	–	–	0.82%	33
2017 Q4	$9.98M	Buy	73,787 +9,671	+15%	+$1.18M	0.44%	44
2017 Q3	$7.9M	Buy	64,116 +400	+0.6%	+$37.5K	0.39%	39
2017 Q2	$6.13M	Buy	+63,716	New	+$8.81M	0.49%	38

Other funds holding SYRE

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Nantahala Capital Management's SYRE Position: Q3 2023 in Review

Nantahala Capital Management sold out of Spyre Therapeutics (SYRE) in Q3 2023, closing a stake of 164,048 shares — an estimated $1.85M sold.

Nantahala Capital Management first reported a position in SYRE in Q2 2017 and held it in 25 quarters. The position peaked at $29.6M in Q2 2020. 29 funds tracked by Wall St. Rank hold SYRE as of Q3 2023.

Nantahala Capital Management reported no remaining Spyre Therapeutics position as of Q3 2023 after selling out during the quarter.
Nantahala Capital Management sold 164,048 Spyre Therapeutics shares in Q3 2023, an estimated $1.85M.
Nantahala Capital Management first reported a position in Spyre Therapeutics in Q2 2017 and held it in 25 quarters.
Nantahala Capital Management's Spyre Therapeutics position peaked at $29.6M in Q2 2020.
29 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2023.

Based on Nantahala Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.